Caprock Group LLC Increases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Caprock Group LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,369 shares of the biopharmaceutical company’s stock after acquiring an additional 3,970 shares during the period. Caprock Group LLC’s holdings in Gilead Sciences were worth $3,914,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in shares of Gilead Sciences in the 3rd quarter worth approximately $25,000. Valued Wealth Advisors LLC lifted its holdings in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 161 shares during the period. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the 4th quarter valued at $29,000. Crews Bank & Trust purchased a new position in shares of Gilead Sciences in the 4th quarter valued at $31,000. Finally, Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences in the 2nd quarter worth $33,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Merdad Parsey sold 164,211 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock worth $42,130,461 in the last ninety days. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Trading Up 0.3 %

Shares of NASDAQ:GILD opened at $97.20 on Friday. The company has a market capitalization of $121.14 billion, a PE ratio of 1,080.00, a PEG ratio of 1.34 and a beta of 0.18. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The business has a 50 day moving average of $92.28 and a two-hundred day moving average of $85.59. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the firm posted $2.29 earnings per share. The firm’s quarterly revenue was up 7.0% compared to the same quarter last year. As a group, analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on GILD. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Royal Bank of Canada reissued a “sector perform” rating and set a $84.00 target price on shares of Gilead Sciences in a research report on Wednesday, December 11th. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. BMO Capital Markets raised their price objective on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Finally, Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $87.00 to $113.00 in a research report on Friday, January 10th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.